Skip to main content

James D. Campbell, MD, MS

Academic Title:


Primary Appointment:


Administrative Title:

Interim Division Head of Pediatric Infectious Disease and Tropical Pediatrics


HSF1, Room 480

Phone (Primary):

(410) 706-5328

Phone (Secondary):

(410) 706-7284


(410) 706-2999

Education and Training

Georgetown University College of Arts and Sciences (magna cum laude), B.S., Biology and Theology, 1987

Columbia University College of Physicians and Surgeons (Alpha Omega Alpha Honor Medical Society), M.D., 1991

Residency, National Naval Medical Center, Pediatrics, 1991-1994

Fellowship, University of Maryland Medical System, Pediatric Infectious Diseases, 1998-2001

Research Fellow, University of Maryland School of Medicine, Pediatrics, 1999-2001

University of Maryland School of Medicine, M.S., Epidemiology and Biostatistics, 2006


Dr. Campbell has been a faculty member at the University of Maryland School of Medicine since 2001. From 2007 to 2012, he lived and worked in Uganda for the U.S. Centers for Disease Control and Prevention (CDC), mainly in the field of HIV prevention and care. He is one of two Senior Vice Chairs of the Institutional Review Board and Director of the University of Maryland Baltimore Clinical Research Training and Mentoring Program. He is a member of the Committee on Infectious Diseases (COID or “Red Book Committee”) for the American Academy of Pediatrics.

Dr. Campbell is currently involved in a number of research endeavors, including:

  • Evaluating the use of a Group B Streptococcus vaccine in pregnant women.
  • Describing vaccine coverage rates among Ethiopian children in 3 representative woredas (districts).
  • Exploring the ecopathogenesis of Chlamydia trachomatis in sexual networks in Baltimore.
  • Evaluating infant investigational vaccines against RSV, pneumoccoccus, and meningococcus.
  • Evaluating vacccines against COVID-19 in aduts, teens, and children.
  • Evaluating new generation anthrax vaccines. 

Research/Clinical Keywords

Vaccines, vaccine development, pediatrics, infectious diseases, epidemiology, vaccine-preventable diseases, clinical trials, Neisseria meningitidis, Bacillus anthracis, seasonal influenza, pandemic influenza, Haemophilus influenzae type b, smallpox, Streptococcus pneumoniae, HIV, SARS-CoV-2

Highlighted Publications

A complete list of published work is available in MyBibliography.

Travassos MA, Beyane B, Adam Z, Campbell JD, Mulholland N, Diarra SS, Kassa T, Oot L, Sequiera J, Reymann M, Blackwelder WC, Wu Y, Ruslanova I, Goswami J, Sow SO, Pasetti MF, Steinglass R, Kebede A, Levine MM. Immunization coverage surveys and linked biomarker serosurveys in three regions in Ethiopia. PLoS ONE. 2016 Mar 2.

Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M, Traore A, Coulibaly F, Kodio M, Onwuchekwa U, Sztein MB, Wahid R, Campbell JD, Kieny M-P, Moorthy V, Imoukhuede EB, Rampling T, Roman F, De Ryck I, Bellamy AR, Dally L, Mbaya OT, Ploquin A, Zhou Y, Stanley DA, Bailer R, Koup RA, Roederer M, Ledgerwood J, Hill AVS, Ballou WR, Sullivan N, Graham B, Levine MM. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: A phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016 Jan;16(1):31-42.

Travassos MA, Beyene B, Adam Z, Campbell JD, Mulholland N, Diarra SS, Kassa T, Oot L, Sequeira J, Reymann M, Blackwelder WC, Pasetti MF, Sow SO, Steinglass R, Kebede A, Levine MM. Strategies for coordination of a serosurvey in parallel with an immunization coverage survey. Am J Trop Med Hyg. 2015 Aug 5;93(2):416–424.

Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Coombs RW, Hendrix C, Marzinke MA, Frenkel L, Haberer JE, Bangsberg D, Celum C, for the Partners PrEP Study Team. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infect Dis. 2014 Nov 14;14(11):1055-1064.

Additional Publication Citations

Testing the safety, tolerability, and efficacy of important vaccines. One of the main themes of Dr. Campbell’s career is the careful clinical evaluation of vaccines in all phases of development.

Testing the safety, tolerability, and efficacy of HIV pre-exposure prophylaxis and evaluating home-based AIDS care. While living in Kampala, Uganda and working for the Centers for Disease Control and Prevention, Dr. Campbell evaluated a home-based AIDS care program and the use of antiretrovirals in preventing HIV transmission to the negative partners in heterosexual discordant couples. As a result of the latter work, tenofovir/emtricitabine was approved by the FDA for HIV prophylaxis.

Investigating the epidemiology of vaccine-preventable diseases. Dr. Campbell has worked in Mali, Uganda, and Ethiopia on vaccine-preventable disease epidemiology. The work in Mali led to the introduction of Hib vaccine there and the work in Ethiopia aims to assist the Ministry of Health in providing universal childhood vaccination coverage.

Research Interests

Dr. Campbell’s research interests include clinical trials of vaccines in all age groups, epidemiology of vaccine-preventable diseases, and HIV prevention. He has performed trials of vaccines against many organisms, including Neisseria meningitidis, Bacillus anthracis, seasonal influenza, pandemic influenza, and smallpox. Dr. Campbell has overseen trials for innovative vaccine administration techniques and coordinated vaccine trials of childhood immunizations at three pediatric clinic vaccine sites in Maryland.

He helped establish and oversee a microbiology laboratory at the pediatric hospital in Bamako, Mali where they investigated the causes of invasive bacterial infections, particularly Streptococcus pneumoniae and Haemophilus influenzae type b. From 2007 to 2012, he was a medical officer/epidemiologist with CDC’s Division of HIV/AIDS Prevention and the in-country Associate Director for Science in Kampala, Uganda. Dr. Campbell's work in Uganda included HIV prevention trials and research on Nodding Syndrome and other outbreaks.

Clinical Specialty Details

Dr. Campbell sees patients and cares for children on the Pediatric Infectious Diseases Service at the University of Maryland Hospital for Children. This service includes both inpatient and outpatient referrals.

Awards and Affiliations

2021: Pediatrician of the Year, Maryland State Chapter of the American Academy of Pediatrics

2015, 2017, 2020, 2021: Baltimore Magazine’s Best Doctors: Pediatric Infectious Diseases

2012: Appreciation Award, The AIDS Support Organization (TASO)

2011: U.S. Embassy Uganda, Franklin Award for participation in identifying an outbreak of Yellow Fever in the north of Uganda

2009: U.S. Embassy Uganda, Meritorious Service Award for leadership in healthcare research in Uganda

2004: America’s Top Pediatricians Listing, Consumers’ Research Council of America

2004: Nomination, Maryland Immunization Excellence Award, Maryland Partnership for Prevention

1999: Alexander J. Schaffer Teaching Award for Outstanding Contributions to Housestaff Education, University of Maryland Medical Center

1998: Navy Commendation Medal

1997/1998: Outstanding Pediatric Teacher, National Naval Medical Center and Walter Reed Army Medical Center

1994: Outstanding Pediatric Teacher, Uniformed Services University of the Health Sciences

Grants and Contracts

2012-present   James D. Campbell (Investigator, 5%) PI MM Levine

                        “Assesment of the Effectiveness of Infant Immunization Services in Ethiopia”

                                    Sponsor: John Snow International

                                    Funder: The Bill and Melinda Gates Foundation (OPP1017350)                             

                                    Total direct costs: $940,520

                                    Role: inform an Ethiopian Federal Ministry of Health (FMPH) evidence-based decision on nationwide universal child immunization; supervised the serosurvey while living in Ethoipia for 1 month in 2013 and in 2016


2013-present  James D. Campbell (Co-Principal Investigator, 20%) PI K Kotloff

                                    “Vaccine and Treatment Evaluation Units (VTEU-Clinical testing of vaccines and related products in human subjects.)  Award HHSN272201300022I (9/16/2013- 9/15/2023).

                                      Sponsor: National Institutes of Health, NIAID. (peer reviewed)

                                    Annual direct costs: IDIQ- minimum $10,000; max $95,170,200.

                                    Role: major role as an investigator and manager, includes acting as PI for multiple vaccine trials including DMID 17-0093, a Phase II study of anthrax vaccine with CPG7909 adjuvant



2018-present   James D. Campbell (PI, 5%)

                                    “Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers” (MET42                                   BB-IND #: 14171)

                                    Sponsor: Sanofi

                                    Total estimated direct costs: $172,644.03

                                    Role: As PI, I oversee the work performed at The Pediatric Center site in Frederick, Maryland where infants are enrolled.


2018-present   James D. Campbell (PI, 5%)

                                    “Double-Blind, Randomized, Placebo-Controlled, Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy, and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in Healthy Seronegative Women, 16 to 35 Years of Age” (V160-002)

                                    Sponsor: Merck

                                    Total estimated direct costs: $210,719.18

                                    Role: As PI, I oversee the work performed at The Pediatric Center site in Frederick, Maryland, the Pediatrics at Midtown site in Baltimore, and the site at the Center for Vaccine Development in Baltimore, where participants will be enrolled.


2018-present   James D. Campbell (PI, 5%)

                                    “A Phase IIIB, Randomized, Observer-Blind, Placebo-Controlled Multicenter Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-Valent Pneumococcal Vaccine When Administered Concomitantly with Routine Vaccines to Healthy Infants” (V72_57)

                                    Sponsor: GSK Biologicals

                                    Total estimated direct costs: $191,842.31

                                    Role: As PI, I will oversee the work performed at the Pediatrics at Midtown site in Baltimore, where infants will be enrolled.


2019-present   James D. Campbell (PI, 5%)

                                    “A study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals’ RSV investigational vaccine based on viral proteins encoded by chimpanzee-derived adenovector (ChAd155-RSV) (GSK3389245A) in infants.” GSK Protocol number 204894 (RSV PED-011)

                                    Sponsor: GSK Biologicals

                                    Total estimated direct costs: $68,855.38

                                    Role: As PI, I will oversee the work performed at the Pediatrics at Midtown site in Baltimore, where infants will be enrolled.


2020-present   James D. Campbell (PI, 5%)

                                    “A phase 3 randomized, double blind trial to evaluate the safety and immunogenicity of a 20 valent pneumococcal conjugate vaccine in healthy infants. Pfizer B7471011

                                    Sponsor: Pfizer

                                    Total estimated direct costs: $TBD

                                    Role: As PI, I will oversee the work performed at the Pediatrics at Midtown site in Baltimore and The Pediatric Center in Frederick, where infants will be enrolled.


2020-present   James D. Campbell (co-Director, 5%)

                                    “Collaborative Influenza Vaccine Innovative Centers (CIVICs)”    

                                    Sponsor: DMID/NIAID/NIH, Award 75N93019C00055

                                    Total estimated direct costs: $2,958,965 (core only; additional funds for each project up to $200 million)

                                    Dates: 09/16/2019 – 06/15/2026

                                    Role: As co-director, I help the director to oversee the work performed in this award, primarily in the role of testing influenza vaccines in pregnant women and children (eg, I am coordinating and site PI for a study of FluGen’s Phase II intranasal influenza vaccine in children).